Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Oric Pharmaceuticals (ORIC) Non Operating Income (2019 - 2026)

Oric Pharmaceuticals filings provide 8 years of Non Operating Income readings, the most recent being $3.9 million for Q1 2026.

  • Quarterly Non Operating Income rose 42.83% to $3.9 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $14.7 million through Mar 2026, up 6.72% year-over-year, with the annual reading at $13.5 million for FY2025, 10.05% down from the prior year.
  • Non Operating Income hit $3.9 million in Q1 2026 for Oric Pharmaceuticals, down from $4.0 million in the prior quarter.
  • Across five years, Non Operating Income topped out at $4.1 million in Q3 2025 and bottomed at $99000.0 in Q1 2022.
  • Average Non Operating Income over 5 years is $2.7 million, with a median of $3.1 million recorded in 2023.
  • The largest annual shift saw Non Operating Income soared 3641.18% in 2022 before it tumbled 33.18% in 2025.
  • Oric Pharmaceuticals' Non Operating Income stood at $1.3 million in 2022, then skyrocketed by 143.55% to $3.1 million in 2023, then rose by 5.33% to $3.3 million in 2024, then increased by 24.0% to $4.0 million in 2025, then decreased by 4.79% to $3.9 million in 2026.
  • Per Business Quant, the three most recent readings for ORIC's Non Operating Income are $3.9 million (Q1 2026), $4.0 million (Q4 2025), and $4.1 million (Q3 2025).